Long-term but Not Short-term Aspirin Treatment Attenuates Diabetes-associated Learning and Memory Decline in Mice

Abstract

Increasing studies have shown that the patients with diabetes mellitus have an increased risk of cognitive impairment, dementia, and neurodegeneration. The present study was designed to evaluate the effect of aspirin on diabetes-associated learning and memory decline in mice. Diabetes was induced by a single intraperitoneal injection of streptozocin (150 mg/kg body weight) in C57BL/6 mice. The mice were administered with aspirin at a dose of 30 mg/kg by intragastric administration once a day for 1, 4 or 8 weeks respectively. 8 weeks after aspirin or vehicle treatment, the effect of aspirin on diabetes-associated learning and memory decline in mice was investigated by evaluating the mean escape latency and the percentage of time spent in target quadrant. The TNF-α, IL-1β contents, and acetylcholinesterase activity in hippocampus were assayed as well. The results showed that administration with aspirin for 4 weeks or 8 weeks significantly reduced the mean escape latency, the acetylcholinesterase activity, the TNF-α, IL-1β levels and increased the percentage of time spent in target quadrant. However, treatment with aspirin for 1 week did not ameliorate diabetes-associated learning and memory decline. The present study demonstrated that long-term aspirin treatment attenuates diabetes-associated learning and memory decline in mice, and that the effect of aspirin was related to its anti-inflammatory potency.

Key words

aspirin - diabetes - learning - memory

References

• 1 Akassoglou K, Probert L, Kontogeorgos G. et al . Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice.  J Immunol. 1997;  158 438-445
• 2 Akiyama H, Arai T, Kondo H. et al . Cell mediators of inflammation in the Alzheimer disease brain.  Alzheimer Dis Assoc Disord. 2000;  14 S47-S53
• 3 Akomolafe A, Beiser A, Meigs JB. et al . Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study.  Arch Neurol. 2006;  63 1551-1555
• 4 Barnum SR, Jones JL, Muller-Ladner U. et al . Chronic complement C3 gene expression in the CNS of transgenic mice with astrocyte-targeted interleukin-6 expression.  Glia. 1996;  18 107-117
• 5 Bierhaus A, Humpert PM, Nawroth PP. Linking stress to inflammation.  Anesthesiol Clin. 2006;  24 325-340
• 6 Breitner JC. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal.  Neurobiol Aging. 1996;  17 789-794
• 7 Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes.  Trends Immunol. 2004;  25 4-7
• 8 Das S, Potter H. Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1.  Neuron. 1995;  14 447-456
• 9 Ellman GL, Courtney KD, Andres VJ. et al . A new and rapid colorimetric determination of acetylcholinesterase activity.  Biochem Pharmacol. 1961;  7 88-95
• 10 Heneka MT, O’Banion MK. Inflammatory processes in Alzheimer's disease.  J Neuroimmunol. 2007;  184 69-91
• 11 Li L, Holscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review.  Brain Res Rev. 2007;  56 384-402
• 12 Li Y, Liu L, Kang J. et al . Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression.  J Neurosci. 2000;  20 149-155
• 13 Lowry OH, Rosebrough NJ, Farr AL. et al . Protein measurement with the Folin phenol reagent.  J Biol Chem. 1951;  193 265-275
• 14 Mackenzie IR. Postmortem studies of the effect of anti-inflammatory drugs on Alzheimer-type pathology and associated inflammation.  Neurobiol Aging. 2001;  22 819-822
• 15 Morris R. Developments of a water-maze procedure for studying spatial learning in the rat.  J Neurosci Methods. 1984;  11 47-60
• 16 Nawroth PP, Rudofsky G, Humpert P. Have we understood diabetes? New tasks for diagnosis and therapy.  Exp Clin Endocrinol Diabetes. 2010;  118 1-3
• 17 Ott A, Stolk RP, van Harskamp F. et al . Diabetes mellitus and the risk of dementia: The Rotterdam Study.  Neurology. 1999;  53 1937-1942
• 18 Rich JB, Rasmusson DX, Folstein MF. et al . Nonsteroidal anti-inflammatory drugs in Alzheimer's disease.  Neurology. 1995;  45 51-55
• 19 Rogers J, Webster S, Lue LF. et al . Inflammation and Alzheimer's disease pathogenesis.  Neurobiol Aging. 1996;  17 681-686
• 20 Sun MK, Alkon DL. Links between Alzheimer's disease and diabetes.  Drugs Today (Barc). 2006;  42 481-489
• 21 Temelkova-Kurktschiev T, Henkel E, Koehler C. et al . Subclinical inflammation in newly detected Type II diabetes and impaired glucose tolerance.  Diabetologia. 2002;  45 151
• 22 van den Berg E, de Craen AJ, Biessels GJ. et al . The impact of diabetes mellitus on cognitive decline in the oldest of the old: a prospective population-based study.  Diabetologia. 2006;  49 2015-2023
• 23 Wang T, Fu FH, Han B. et al . Aspirin attenuates cerebral ischemic injury in diabetic rats.  Exp Clin Endocrinol Diabetes. 2009;  117 181-185
• 24 Wenk GL, Willard LB. The neural mechanisms underlying cholinergic cell death within the basal forebrain.  Int J Dev Neurosci. 1998;  16 729-735
• 25 Whitmer RA. Type 2 diabetes and risk of cognitive impairment and dementia.  Curr Neurol Neurosci Rep. 2007;  7 373-380

Correspondence